HC Wainwright Boosts TG Therapeutics (NASDAQ:TGTX) Price Target to $49.00

TG Therapeutics (NASDAQ:TGTX) had its price objective increased by HC Wainwright from $45.00 to $49.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the stock. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a report on Thursday, February 29th. B. Riley increased their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a report on Monday, February 5th. LADENBURG THALM/SH SH increased their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a buy rating in a report on Thursday. JPMorgan Chase & Co. reissued an overweight rating and set a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, StockNews.com cut shares of TG Therapeutics from a buy rating to a hold rating in a report on Saturday, February 24th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $29.83.

TG Therapeutics Trading Down 1.4 %

TGTX opened at $16.19 on Thursday. The stock has a market capitalization of $2.50 billion, a PE ratio of 70.39 and a beta of 2.33. The firm’s fifty day moving average price is $15.25 and its 200 day moving average price is $14.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The company’s revenue was up 713.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.28) earnings per share. As a group, research analysts expect that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.20% of the stock is currently owned by insiders.

Institutional Trading of TG Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its stake in shares of TG Therapeutics by 3.9% during the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock valued at $538,000 after purchasing an additional 1,322 shares in the last quarter. Wealth Effects LLC lifted its stake in shares of TG Therapeutics by 17.9% in the 1st quarter. Wealth Effects LLC now owns 16,500 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 2,500 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of TG Therapeutics by 4.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 107,420 shares of the biopharmaceutical company’s stock valued at $1,634,000 after acquiring an additional 4,548 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of TG Therapeutics by 16.9% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock valued at $2,811,000 after acquiring an additional 26,761 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in shares of TG Therapeutics by 55.8% during the first quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 27,437 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.